# US 2025/0206809 A1 · Anti-etec adhesin protein antibodies and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0206809 A1
- Document ID: US20250206809A1
- Status: Published application
- Kind: A1
- Application number: 19/076,123
- Filed: 2025-03-11
- Published: 2025-06-26
- Earliest claimed: 2020-06-26
- Assignees: University of Massachusetts
- Applicants: University of Massachusetts
- Inventors: Mark S. Klempner; Yang Wang; Lisa Cavacini; Alla Amcheslavsky
- Web page: https://patentgrep.com/patent/US20250206809A1

## CPC

- C07K 16/1232: Escherichia (G)
- A61P 31/04: Antibacterial agents
- G01N 33/56916: {Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/542: {oral/gastrointestinal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/35: Valency
- C07K 2317/522: CH1 domain
- C07K 2317/53: Hinge
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/21: containing a His-tag
- G01N 33/56911: {Bacteria}
- G01N 2333/245: Escherichia (G)
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides anti-ETEC adhesin protein antibodies and methods of using the same.

## Claims

### Claim 1

An isolated VHH antibody that binds an enterotoxigenic E. coli (ETEC) adhesin protein, wherein the antibody comprises a VHH binding domain comprising the following complementary determining regions (CDRs):
(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 177;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 178; and
(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 179.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the VHH binding domain comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 180.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the antibody comprises multiple VHH binding domains.

### Claim 4 (depends on 3)

The antibody of claim 3, comprising the following N-terminal-to-C-terminal structure:
(P3-L3)n3-P2-(L1-P1)n1
wherein P1, P2, and P3 are each an isolated VHH antibody that binds an ETEC adhesin protein,
wherein the antibody comprises a VHH binding domain comprising the following CDRs:
(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 177;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 178; and
(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 179;
L1 and L3 are each independently a linker; and
n1 and n3 are each independently 0 or 1, wherein at least one of n1 and n3 are 1.

### Claim 5 (depends on 3)

The antibody of claim 3, wherein the antibody does not comprise an Fc region.

### Claim 6 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a single VHH binding domain.

### Claim 7 (depends on 6)

The antibody of claim 6, wherein the antibody consists of a single VHH binding domain.

### Claim 8

An isolated VHH antibody that binds an ETEC adhesin protein, wherein the antibody comprises a VHH binding domain comprising the following CDRs:
(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 177;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 178; and
(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 179;
wherein the antibody is a monoclonal antibody, a humanized antibody, or a chimeric antibody.

### Claim 9 (depends on 8)

The antibody of claim 8, wherein the antibody is an IgA class antibody or an IgG class antibody.

### Claim 10 (depends on 3)

The antibody of claim 3, wherein the antibody comprises an Fc domain comprising a first Fc domain subunit and a second Fc domain subunit, wherein the first Fc domain subunit and the second Fc domain subunit are capable of stable association.

### Claim 11 (depends on 1)

The antibody of claim 1, wherein the antibody is a VHH antibody fragment that binds an ETEC adhesin protein.

### Claim 12 (depends on 1)

An isolated nucleic acid encoding the antibody of claim 1.

### Claim 13 (depends on 12)

A vector comprising the nucleic acid of claim 12.

### Claim 14 (depends on 13)

A host cell comprising the vector of claim 13.

### Claim 15 (depends on 12)

A method of producing a VHH antibody, the method comprising culturing a host cell comprising an expression vector comprising the nucleic acid of claim 12 in a culture medium.

### Claim 16 (depends on 1)

A composition or a pharmaceutical composition comprising the antibody of claim 1.

### Claim 17 (depends on 1)

A method of treating a subject having a disorder associated with an ETEC infection or at risk of developing a disorder associated with an ETEC infection comprising administering to the subject an effective amount of the antibody of claim 1, thereby treating the subject.

### Claim 18 (depends on 1)

A method of detecting an ETEC in a sample from a subject, the method comprising contacting the sample with the antibody of claim 1 under conditions permissive for binding of the antibody to an ETEC and detecting whether a complex is formed between the antibody and the ETEC.

### Claim 19 (depends on 1)

A kit comprising the antibody of claim 1 and a package insert comprising instructions for (a) using the antibody to treat a subject having or at risk of developing a disorder associated with an ETEC infection or (b) using the antibody to detect ETEC.

### Claim 20

An isolated VHH antibody that binds an ETEC adhesin protein, wherein the antibody comprises a VHH binding domain comprising the amino acid sequence of SEQ ID NO: 180.

### Claim 21 (depends on 20)

An isolated nucleic acid encoding the antibody of claim 20.

### Claim 22 (depends on 21)

A vector comprising the nucleic acid of claim 21.

### Claim 23 (depends on 22)

A host cell comprising the vector of claim 22.

### Claim 24 (depends on 21)

A method of producing a VHH antibody, the method comprising culturing a host cell comprising an expression vector comprising the nucleic acid of claim 21 in a culture medium.

### Claim 25 (depends on 20)

A composition or a pharmaceutical composition comprising the antibody of claim 20.

### Claim 26 (depends on 20)

A method of treating a subject having a disorder associated with an ETEC infection or at risk of developing a disorder associated with an ETEC infection comprising administering to the subject an effective amount of the antibody of claim 20, thereby treating the subject.

### Claim 27 (depends on 20)

A method of detecting an ETEC in a sample from a subject, the method comprising contacting the sample with the antibody of claim 20 under conditions permissive for binding of the antibody to an ETEC and detecting whether a complex is formed between the antibody and the ETEC.

### Claim 28 (depends on 20)

A kit comprising the antibody of claim 20 and a package insert comprising instructions for (a) using the antibody to treat a subject having or at risk of developing a disorder associated with an ETEC infection or (b) using the antibody to detect ETEC.
